EGFR VEGF NSCLC VEGF EGFR [31, 32] [ 29] VEGF/ EGFR AE EGFR TKI EGFR TKI [33, 34] [35] [31, 32, 36] NSCLC [37, 38] NSCLC VEGF MoAb [39] aflibercept VEGF Trap aflibercept III [40] NSCLC III NSCLC [36, 37] ZD6474 VEGFR-2 EGFR TKI RET [36] pan-HER/VEGFR BMS-690514 NSCLC [59] T790M BMS -690514 [60] NSCLC pan-HER TKI PF-00299804 HKI-272 XL647 pan-HER TKI ErbB XL647 EGFR HER2 VEGFR-2 EphB4 [61] II NSCLC [62] [63] [64] III E2501 NSCLC II PFS PFS 3.6 vs 1.9 P=0.001 25% 2 [65] NSCLC III Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy, ESCAPE [66] + 4 [67] NSCLC II/III BR.24 [68] 30 mg 45 mg 20 mg / BR.29 [69] NSCLC mTOR [77] mTOR [ -779 RAD001 deforolimus AP23573 ]
[17]
[8]
EGFR mTOR [9, 10] I [18] IGF-1 [78] IGF-1R [22] II IGF-1R NSCLC [79] IGF-1R EGFR NSCLC TKI [11] III IGF-1R NSCLC [25] mTOR IGFR [14] MET MET EGFR VEGF MET [80] vascular disrupting agent, VDA [81] VDA VDA circulating endothelial progenitor cells, CEPs
